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Quercetin with vitamin C and niacin does not
affect body mass or composition
Amy M. Knab, R. Andrew Shanely, Fuxia Jin, Melanie D. Austin, Wei Sha, and
David C. Nieman
Abstract: In vitro and animal data suggest that quercetin affects adipogenesis and basal metabolism; however, whether this
metabolic effect translates to reductions in body mass or improvement in body composition in humans is unknown. This
study investigated 12-week supplementation of 2 different doses of quercetin, combined with vitamin C and niacin, on body
mass and composition in a large, heterogeneous group of adults (n = 941; 60% female, 40% male; 18–85 years of age; 45%
normal body mass index, 30% overweight, 25% obese). Subjects were randomized into 3 groups, with supplements adminis-
tered in double-blind fashion: Q500 = 500 mg quercetin·day–1, Q1000 = 1000 mg quercetin·day–1, and placebo. Quercetin
supplements were consumed twice daily over a 12-week period, and pre- and poststudy body mass and composition meas-
urements were taken in an overnight fasted state. A general linear model was used to predict change in body mass and com-
position across groups with adjustment for demographic and lifestyle factors. Plasma quercetin increased in a dose-
responsive manner in both Q500 and Q1000 groups relative to placebo. After adjustment for confounders, no significant dif-
ferences in body mass (males interaction p value = 0.721, females p = 0.366) or body composition (males p = 0.650, fe-
males p = 0.639) were found between Q500 or Q1000 groups compared with placebo. No group differences in body mass
or body composition were found in a subgroup of overweight and obese subjects. High-dose quercetin supplementation (500
and 1000 mg·day–1) for 12 weeks in a large, heterogeneous group of adults did not affect body mass or composition.
Key words: body fat, BMI, body mass, flavonoid.
Résumé : Il semble d’après des observations in vitro et sur des animaux que la quercétine modifie l’adipogenèse et le méta-
bolisme de base; néanmoins, on ne sait pas si cet effet entraîne chez les humains une perte de masse ou une amélioration
de la composition corporelle. Dans cette étude, on analyse sur une période de 12 semaines l’effet d’une supplémentation
(2 doses différentes) en quercétine combinée à de la vitamine C et à de la niacine sur la masse et la composition corporelles
d’un groupe hétérogène d’adultes formant un imposant effectif (n = 941, 60 % de femmes 40 % d’hommes, de 18 à 85 ans,
45 % présentant un IMC normal, 30 % un surpoids et 25 %, de l’obésité). On répartit aléatoirement les sujets en trois grou-
pes recevant en double insu l’une des 3 supplémentations suivantes : 500 mg de quercétine·jour–1 (Q500), 1000 mg de quer-
cétine·jour–1 (Q1000) ou un placebo. Les sujets prennent les suppléments à raison de 2 fois par jour sur une période de
12 semaines; au début et à la fin de cette période, on évalue la masse et la composition corporelles après un jeûne de toute
une nuit. On applique un modèle linéaire général pour prédire les variations de la masse et de la composition corporelles
des trois groupes tout en prenant en compte des variables démographiques et des facteurs du mode de vie. La concentration
plasmatique de quercétine augmente selon une relation dose/effet chez les deux groupes recevant de la quercétine comparati-
vement au groupe recevant le placebo. Après correction pour les variables parasites, on n’observe aucune différence signifi-
cative de masse corporelle (interaction: hommes, p = 0,721; femmes, p = 0,366) ou de composition corporelle (hommes,
p = 0,650; femmes, p = 0,639) entre les groupes Q500 et Q1000 comparativement au groupe placebo. En outre, on n’ob-
serve aucune différence de masse ou de composition corporelle dans un sous-groupe de sujets obèses et présentant un sur-
poids. De fortes doses de supplémentation en quercétine (500 et 1000 mg·jour–1) durant 12 semaines chez un important
groupe hétérogène d’adultes ne modifient ni la masse corporelle ni la composition corporelle.
Mots‐clés : gras corporel, BMI, masse corporelle, flavonoïde.
[Traduit par la Rédaction]
Introduction
The obesity pandemic has accelerated cell, animal, and hu-
man research on the anti-obesity effects of flavonoids (Borch-
ardt and Huber 1975; Melzig 1996; Hase et al. 2001; Nagao
et al. 2001, 2005, 2007; Singh et al. 2003; Alexander 2006;
Greenberg et al. 2006; Harwood et al. 2007; Bose et al.
2008; Egert et al. 2008; Ito et al. 2008; Stewart et al. 2008;
Liu et al. 2009; Faria et al. 2010; Grove and Lambert 2010;
Zhu et al. 2010). For example, several animal studies indicate
that 3–15 weeks of supplementation with green tea extract
and epigallocatechin gallate (EGCG) reduce body mass and
fat mass (Bose et al. 2008; Ito et al. 2008). The catechins in
green tea may increase thermogenesis and fat oxidation by
inhibiting catechol-O-methyltransferase, leading to increased
expression of norepinephrine and heightened sympathetic
nervous system activity (Borchardt and Huber 1975). Epide-
miological research supports the anti-obesity influence of
green tea intake (Grove and Lambert 2010), and controlled
human trials indicate a small but significant decrease in
body mass, waist circumference, and body fat in subjects
randomized to green tea extract supplementation (Hase et al.
2001; Nagao et al. 2001, 2005, 2007). Other polyphenols
such as soy isoflavones demonstrate positive effects on
weight loss in humans. For example, 6 months of supplemen-
tation with 15 g soy protein and 100 mg isoflavones signifi-
cantly reduced body mass and body fat percentage in
postmenopausal Chinese women (Liu et al. 2009).
Aside from tea catechins, quercetin is the most widely con-
sumed flavonoid and is found in foods such as onions, ber-
ries, and apples (Harwood et al. 2007). Quercetin crosses the
blood–brain barrier (Faria et al. 2010), inhibits adenosine re-
ceptor activity (Melzig 1996; Alexander 2006), and inhibits
catechol-O-methyltransferase by acting as a competing sub-
strate (Singh et al. 2003; Zhu et al. 2010). Studies also indi-
cate that quercetin affects adipogenesis and causes apoptosis
of adipocytes through the adenosine monophosphate-activated
protein kinase (AMPK) pathway (Ahn et al. 2008). This
mode of action is similar to that of caffeine, which has
been related to small but significant decreases in body
mass (Greenberg et al. 2006). Animal and human data on
the anti-obesity influences of quercetin are limited. In one
study, mice fed a high-fat diet with quercetin supplements
exhibited transiently increased energy expenditure after
3 weeks and decreased inflammatory markers, but without
measurable effects on body mass or fat mass (Stewart et al.
2008). One small-scale human study reported no effects of
2-week, low-dose quercetin supplementation (50, 100, or
150 mg·day–1) on body mass or body composition in
healthy subjects (Egert et al. 2008).
EGCG and quercetin have similar mechanisms of action,
and we hypothesized that long-term supplementation of high
doses of quercetin would cause small but biologically signifi-
cant decreases in body mass and fat in male and female sub-
jects. Specifically, this study measured the influence of 2
quercetin doses (500 or 1000 mg·day–1) over a 12-week pe-
riod on body mass and composition in a large group (n =
933) of male and female adults. The quercetin in this investi-
gation was combined with vitamin C and niacin to improve
quercetin bioavailability, as explained in the Methods. The
quercetin dose is based on animal studies showing increased
mitochondrial biogenesis beginning at 12.5 mg quercetin·(kg
body mass)–1 (Davis et al. 2009).
Materials and methods
Subjects
Male and female noninstitutionalized subjects (n = 941),
18–85 years of age, were recruited from the community via
mass advertising. Approximately half the subjects were
studied during a 12-week period from January to April
2008, and the second half from August to November 2008.
Women who were pregnant or lactating were excluded from
the study, but no other exclusion criteria were employed.
Both diseased and nondiseased subjects were allowed to par-
ticipate, and during recruitment, subjects were stratified by
sex (∼40% male, 60% female), age (40% young adult, 18–
40 years of age; 40% middle-aged, 41–65; and 20% elderly,
65 and over), and body mass index (BMI) (45% normal, or
18.5–24.9 kg·m–2; 30% overweight, or 25–29.9 kg·m–2; and
25% obese, or ≥30 kg·m–2) to ensure representation of these
various subgroups. Thirty-seven percent of subjects reported
past or current history for one or more chronic diseases: hy-
pertension (19%), arthritis (16%), cancer (6%), cardiovascular
disease (4%), and (or) diabetes (4%). During the study, sub-
jects agreed to avoid any other supplements containing quer-
cetin; no other restrictions were placed on diet, supplement
usage, or medications. Several papers have recently been
published from this large study, with a focus on quercetin
supplementation effects on inflammation, oxidative stress,
plasma quercetin response, immune function, and upper res-
piratory tract infections (Heinz et al. 2010a, 2010b; Jin et al.
2010; Shanely et al. 2010). All experimental procedures were
approved by the Appalachian State University Institutional
Review Board, and written informed consent was obtained
from each subject.
Research design
Subjects were randomized to 1 of 3 groups: Q500 (500 mg
quercetin·day–1), Q1000 (1000 mg quercetin·day–1), or pla-
cebo (PL). Supplements were administered utilizing double-
blind procedures. Subjects ingested 2 soft chew supplements
twice daily (upon awakening, and between 1400 hours and
the last meal of the day) during the 12-week study period.
Supplements were prepared by Nutravail Technologies
(Chantilly, Va., USA) with Quercegen Pharmaceuticals (New-
ton, Mass., USA), and were soft, individually wrapped chews
(5.3 g·piece–1) that contained either 125 or 250 mg quercetin,
125 or 250 mg vitamin C (ascorbic acid and sodium ascor-
bate), 5 or 10 mg niacin, and 20 kcal of sugars in a carnauba
wax, soy lecithin, corn starch, glycerine, and palm oil base
colored with FD&C yellows 5 and 6. Vitamin C and niacin
were added to the supplements based on unpublished animal
data indicating that these compounds increase the bioavail-
ability of quercetin. Placebo supplements were prepared ex-
actly the same way minus the quercetin, ascorbic acid,
sodium ascorbate, and niacin. Subjects ingested the soft
chew supplements for 12 weeks. The following information
was also reported via monthly logs by each subject: adher-
ence to the supplementation regimen, physical activity and
diet status, change in disease status and medication use, as
well as gastrointestinal (constipation, heartburn, bloating,
diarrhea, nausea, vomiting), skin (rash, dryness, flushing), al-
lergy, and mental (energy, headache, stress, focus and con-
centration) symptoms.
Outcome measures: body composition, body mass, and
lifestyle risk factors
Subjects were required to come to the laboratory in an
overnight fasted state (no food within 9 h of the test), in nor-
mal hydration status, with no alcohol or caffeine within 9 h
of the test, no vigorous exercise within 24 h of the test, and
routine urination upon waking up. Height was measured us-
ing a stadiometer, while body mass and body composition
were measured using a Tanita (model TBF 305) bioelectrical
impedance (BIA) scale (Tanita Corporation of America Inc.,
Arlington Heights, Ill., USA). The Tanita BIA scale has been
validated as an accurate testing device for body composition
(Brock et al. 2001). Similarly, Utter et al. showed no differ-
ences between underwater weighing and BIA measurement
using the Tanita scale in obese and nonobese women (Utter
et al. 1999). In a separate study, between-day instrument pre-
cision was measured to be between 1% and 3.5% (Nunez et
al. 1997). Testing took place between 0700 and 0930 hours.
Subjects were measured while standing erect, wearing light
clothing, with bare feet on the analyzer’s foot pads. Measure-
ments were taken pre- and poststudy.
Subjects completed a lifestyle habit survey 2 weeks prior
to the first laboratory visit of the study. The survey was a
comprehensive questionnaire and posted on http://www.
SurveyMonkey.com (Portland, Ore., USA). For subjects
without Internet access, hard copies of the survey were
completed. Semiquantitative food frequency questionnaires
were used to assess intake of fruits, vegetables, cereals,
meat, dairy, and fat. Subjects were asked to check a box in-
dicating “on average, how many servings of… do you eat
per day”, and serving size information was provided in ac-
cordance with MyPyramid Food Guide (US Department of
Health and Human Services and US Department of Agricul-
ture 2005). Similarly, exercise frequency was assessed using
a questionnaire, where subjects answered the following
question: “Outside of your normal work or daily responsi-
bilities, how often do you engage in exercise that at least
moderately increases your breathing and heart rate, and
makes you sweat, for at least 20 minutes.” Responses were
limited to seldom or never, less than 1, 1–2, 3–4, or 5 or
more times per week. Based on the subject’s response, they
were classified into aerobic frequency tertiles of ≤1, 1–4,
or ≥5. Other lifestyle factors such as chronic disease status,
smoking, weight loss history, fatty food intake, and cigarette
habits were assess in a similar manner.
Plasma quercetin measurement
Plasma quercetin was measured as previously described
(Jin et al. 2010). Blood samples were drawn into heparin
tubes after an overnight fast in the morning (0700–
0900 hours) before and after the 12-week supplementation
period. A subgroup of 170 subjects had their blood drawn
monthly following the starting point of supplementation.
Blood was immediately centrifuged at 4000g at 4 °C, and ali-
quots of plasma samples were snap-frozen to store at –80 °C.
Quercetin and its conjugates were measured as previously
described (Nieman et al. 2007a, 2007b, 2007c, 2009). To
each 500 µL human plasma, 10% DL-dithiothreitol solution
(10 µL) was added prior to the addition of 50 µL of
0.58 mol·L–1 acetic acid. The mixture was then spiked with
10 µL of 0.356 µmol·L–1 fisetin internal standard. To this, a
mixture of 50 µL enzyme b-glucuronidase–arylsulfatase and
crude extract from Helix pomatia (Roche Diagnostics Corp.,
Indianapolis, Ind., USA) was added. The mixture was incu-
bated for 2 h at 37 °C. Then 500 µL of 0.01 mol·L–1 oxalic
acid was added to stop the enzymatic reactions. The micro-
plate was vortexed for 1 min before centrifugation at
3000 r·min–1 (1109g) for 17 min (Allegra X-22R centrifuge;
Beckman Coulter, Fullerton, Calif., USA).
Waters (Milford, Mass., USA) Oasis HLB 96-well sample
extraction plates (30 mg, 30 µm) were conditioned with
1.0 mL methanol, 0.5 mL 0.01 mol·L–1 oxalic acid, and
1.0 mL distilled water sequentially. The waste was pulled
through at a speed of less than 0.2 mL·min–1. The superna-
tant of the enzyme hydrolysis mixture was then loaded in
the extraction plate, and the samples were washed with
1.0 mL of 5% methanol in 0.5 mol·L–1 phosphoric acid and
1.0 mL of 50% methanol in 0.5 mol·L–1 phosphoric acid sol-
ution, respectively. Finally, samples were eluted with 2 vol-
umes of 0.5 mL methanol, and the eluents were combined
into a clean microplate with elution flow rate kept at less
than 0.2 mL·min–1. A 10% DL-dithiothreitol solution (10 µL)
was added prior to solvent evaporation at 30 °C with N2
blowing through. The dried samples were reconstituted into
50–50 methanol–water for high-performance liquid chroma-
tography analysis.
Chromatographic analysis was performed using the Ulti-
mate 3000 HPLC-PDA system (Dionex Corporation, Sunny-
vale, Calif., USA) using a Gemini C18 column (150 mm ×
4.6 mm, 100 A, 5 µm) with Gemini C18 4 mm × 3.0 mm
SecurityGuard cartridges (Phenomenex, Torrance, Calif.,
USA). The column was kept at 30 °C, and the flow rate was
1.0 mL·min–1. Separation was carried out using a 15-min gra-
dient of acetonitrile containing 0.1% formic acid and water
containing 0.1% formic acid. The PDA detector was set to
monitor at 375 nm as well as scanning from 250 to 700 nm,
and the injection volume was kept at 50 µL.
Statistics
Data are expressed as mean values with their standard de-
viations. Subject characteristics were contrasted between
groups using 1-way ANOVA (Table 1). Data were analyzed
using a 3 (group) × 2 (time) repeated-measures ANOVA, be-
tween-groups design, with post hoc analysis using independ-
ent Student’s t tests that contrasted pre- to
postsupplementation changes of Q500 and Q1000 with pla-
cebo for each sex (Tables 2 and 3). Change in body mass
was correlated with change in plasma quercetin using Pear-
son correlations (Fig. 1). c-square analysis was used to deter-
mine whether lifestyle factors (categorical data) differed
across groups (Table 4).
In addition, to study whether there is a significant quercetin
effect on the change of body mass or percent body fat, we
used a general linear model (GLM) to predict change in
body mass or percent body fat (response variable) with quer-
cetin intake (placebo, Q500, and Q1000 groups) after adjust-
ing for confounding variables. Stepwise selection in the
GLMSELECT procedure in SAS (version 9.1.3; SAS Institute
Inc., Cary, N.C., USA) was used to determine confounding
variables. The potential confounders that GLMSELECT se-
lected from were sex (male, female), age, exercise frequency,
cigarette smoking habit, self-reported diet intake by food
groups (tertiles of fruit, vegetable, red meat food groups, and
fatty food frequency), weight loss history, chronic disease
status, and interaction between each confounding variable
and quercetin. Stepwise selection removes nonsignificant
terms from the model based on Akaike’s information cor-
rected criterion. Change in body mass (or percent body fat)
was calculated by subtracting presupplementation from post-
supplementation levels. A contrast was constructed to esti-
mate whether there was a quercetin-related trend in change
of body mass or percent body fat. Outliers with studentized re-
sidual >3.5 or <–3.5 were excluded from the analysis to meet
the normality assumption of the general linear model. This
analysis was applied to all subjects first, and was then ap-
plied to subjects who were overweight (BMI 25–29.9) or
obese (BMI ≥ 30).
Results
Subject characteristics are reported in Table 1. For all
demographic factors listed in Table 1, no prestudy differences
were found between groups. No significant interaction p val-
ues were found for change in body mass or body composition
for each sex, as summarized in Table 2. There was a slight
increase in body mass within groups in both males and fe-
males over the 12-week treatment period (p < 0.001). GLM
analysis, after adjustment for confounding variables, showed
that quercetin was not found to have a significant effect on
Table 1. Subject characteristics.
Placebo Q500 Q1000 Group difference
Total sample size (n) 322 310 309
Male 115 130 125
Female 207 180 184
Age (years)
Male 44.2±17.2 45.3±17.6 46.2±16.8 0.655
Female 47.4±16.2 47.6±15.4 45.8±15.1 0.455
Height (m)
Male 1.78±0.07 1.78±0.07 1.77±0.08 0.359
Female 1.64±0.06 1.65±0.08 1.64±0.06 0.142
BMI (kg·m–2)
Male 27.1±4.6 26.9±5.4 27.9±4.7 0.246
Female 26.4±5.7 26.3±5.7 26.3±6.2 0.98
Marital status (%) S, M, O S, M, O S, M, O
Male 33.0, 53.9, 13.0 27.7, 64.6, 7.7 24.8, 68.8, 6.4 0.136
Female 30.0, 54.1, 15.9 24.4, 58.3, 17.2 31.0, 50.5, 18.5 0.563
Current smoker (%) 5.6 7.8 8.1 0.414
Exercise frequency
No. days per week >5, 1–4, <1 >5, 1–4, <1 >5, 1–4, <1
% of group 20.2, 61.8, 18.0 23.8, 55.6, 20.6 21.4, 53.1, 25.6 0.109
Race (% Caucasian) 93.8 95.8 93.5 0.397
Education (years) 15.5±2.7 15.7±2.9 15.6±2.7 0.871
Note: BMI, body mass index; S, single; M, married; O, other.
Table 2. Body mass and composition of study subjects (values are means ± SD).
Variable Placebo Q500 Q1000
p values for interaction,
time
Body mass (kg)
Males n = 115 n = 130 n = 125
Pre 85.0±15.0 85.2±17.7 87.2±16.6 0.627, <0.001
Post 85.7±14.6 86.1±18.2 87.8±16.3
Females n = 207 n = 180 n = 184
Pre 71.0±15.4 71.7±16.5 70.8±17.4 0.142, <0.001
Post 71.4±15.6 72.4±16.5 71.2±17.5
Body composition (%)
Males
Pre 21.9±9.5 21.8±9.4 24.4±9.2 0.644, <0.001
Post 22.2±9.3 22.4±9.5 25.0±9.2
Females
Pre 34.8±9.6 34.7±9.6 33.9±9.9 0.112, 0.325
Post 34.6±9.7 35.0±9.6 34.1±9.8
Note: Pre, prestudy body mass; Post, poststudy body mass.
the change of body mass (p = 0.0599; ptrend = 0.6782) or
percent body fat (p = 0.1457; ptrend = 0.1016).
Table 3 summarizes data for all subjects with a BMI of 25
or higher and shows that there were no significant interaction
p values for change in body mass or body composition in
male or female overweight and obese subjects. GLM analysis
with adjustment for potential confounders within these over-
weight and obese subjects revealed no group differences for
body mass (p = 0.0718; ptrend = 0.7206) or percent body fat
(p = 0.4682; ptrend = 0.2793).
The 8 factors that were related to body mass and percent
body fat included exercise frequency, fruit intake, vegetable
intake, red meat intake, chronic disease status, smoking,
weight loss history, and visible fat intake. c-square analysis
Table 3. Body mass and composition in overweight and obese individuals (values
are means ± SD).
Variable Placebo Q500 Q1000
p values for interaction,
time
Body mass (kg)
Males n = 69 n = 76 n = 89
Pre 92.7±13.6 94.5±16.9 93.0±15.8 0.357, <0.001
Post 93.4±13.0 95.5±17.5 93.5±15.6
Females n = 105 n = 88 n = 89
Pre 82.2±13.1 83.7±14.7 83.6±16.2 0.737, <0.001
Post 82.8±13.5 84.4±14.7 84.0±16.3
Body composition (%)
Males
Pre 27.6±6.7 27.2±7.7 28.3±7.1 0.637, 0.011
Post 27.8±6.7 27.7±7.8 28.8±7.0
Females
Pre 41.6±5.7 42.0±5.3 41.5±5.8 0.506, 0.151
Post 41.6±5.8 42.2±5.2 41.7±5.8
Note: Pre, prestudy body mass; Post, poststudy body mass.
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Fig. 1. Change in body mass vs. change in plasma quercetin after 12 weeks of supplementation (r = 0.016, p = 0.628).
Table 4. c-square analysis of selected categor-
ical factors across groups.
Confounder c2 p
Exercise frequency 7.57 0.109
Fruit intake 2.19 0.70
Vegetable intake 2.97 0.563
Red meat intake 1.10 0.894
Chronic disease status 0.238 0.888
Smoker vs. nonsmoker 1.76 0.414
Weight loss history 4.96 0.549
Fatty food frequency 0.675 0.714
for these categorical variables showed no significant differen-
ces between groups (Table 4). For percent body fat models,
no confounding variables were selected by the model selec-
tion procedure. For the body mass models, red meat was the
only variable that was selected by the model selection proce-
dure and was found to have a significant effect (p < 0.0001)
on change in body mass in the 12-week study period. Sub-
jects who had high red meat intake had a significantly higher
increase in body mass than subjects with medium or low red
meat intake. In addition, change in body mass after quercetin
concentration was not related to plasma quercetin response,
as shown in Fig. 1.
Discussion
Supplementation with 500 or 1000 mg·day–1 of quercetin
with vitamin C and niacin did not significantly affect body
mass or percent body fat in a large, heterogeneous group of
males and females, or in overweight and obese subjects ana-
lyzed separately. This finding was strengthened by GLM
analysis of group data with 10 demographic and lifestyle
characteristics. Changes in body mass and composition and
plasma quercetin were not related in correlational analysis.
This finding is in concert with animal studies that show no
differences in body mass after quercetin supplementation.
Stewart et al. (2008) found that feeding quercetin to mice on
high-fat diets caused an initial increase in energy expenditure
(after 3 weeks), but this increase in energy expenditure was
not detected after long-term supplementation (8 weeks). Re-
gardless of the energy expenditure differences, there were no
differences in body mass or body composition between mice
fed quercetin versus placebo at any time point (Stewart et al.
2008). In separate studies, no differences in body mass were
detected after supplementation with quercetin in rats fed ei-
ther high-fat or high-fat–high-sucrose chow (Barrenetxe et al.
2006; Yamamoto and Oue 2006).
Similar to our findings, Egert et al. (2008) showed that
low doses of quercetin supplements (50, 100, and
150 mg·day–1) for 2 weeks did not alter body mass or percent
body fat in healthy human subjects. In addition, in a subset
of subjects, quercetin failed to alter resting energy expendi-
ture (Egert et al. 2008). Thus, quercetin supplements tested
over a wide range of doses (50–1000 mg·day–1) have not
been linked to changes in body mass or composition.
Quercetin is hypothesized to have similar but slightly dif-
ferent mechanisms of action from that of caffeine or green
tea by increasing catacholamines in the brain and circulation,
as well as suppressing adipogenesis. The green tea catechin
EGCG has produced positive effects on body mass and com-
position in animals (Bose et al. 2008; Ito et al. 2008).
Although quercetin had no effect on body mass or composi-
tion in the current study, small effects on body mass have
been observed with tea catechins (Hase et al. 2001; Nagao et
al. 2001, 2005, 2007; Harada et al. 2005) and other polyphe-
nols such as soy flavonoids (Jenkins et al. 2002; Liu et al.
2009). However, Park et al. (2008) found that a combination
of genistein, quercetin, and resveratrol was more effective at
inhibiting adipogenesis and inducing apoptosis in human adi-
pocytes than any individual compound alone.
Thus, although a multitude of individual natural com-
pounds have been identified to have beneficial effects on adi-
pocytes in vitro, “targeted monotherapy” in animals and
humans has exhibited little success (Relume et al. 2008). An-
dersen et al. (2010) also highlighted that the pharmacological
doses used successfully in vitro often fail to affect adipogen-
esis in animal or human models; however, combinations of
photochemical, as opposed to isolated compounds, may be
more beneficial in eliciting desired weight loss effects. For
example, Nakazato et al. (2006) found that supplementing
rats with 5% apple polyphenols in the diet resulted in signifi-
cantly reduced adipose tissue masses and reduced adipogene-
sis compared to that in control animals. Also, Nieman et al.
(2009) found that 2 weeks of supplementation with quercetin
combined with EGCG resulted in a significant reduction in
inflammation following heavy exertion in cyclists. Thus,
combining several natural compounds to target multiple sig-
nal transduction pathways may be more efficacious in the
treatment of obesity than treatment with single compounds
in isolation (Relume et al. 2008). Quercetin, combined with
vitamin C and niacin for improved bioavailability of querce-
tin, did not elicit any benefit on body mass or composition in
the current human study; however, the next step in this line
of research will be to combine quercetin with other natural
compounds that will target multiple signaling pathways in-
volved in thermogenesis, fat oxidation, and adipogenesis to
effectively alter obesity-related risk factors.
The current study confirms, on a large scale, that even
high doses of quercetin, combined with vitamin C and niacin,
do not affect body mass or composition in the general human
population. Although quercetin does not effectively reduce
body mass in a large population of subjects, including over-
weight and obese individuals, additional research is war-
ranted focusing on a cocktail approach in combining
multiple bioactive polyphenols that may together induce a
small but significant decrease in body fat.
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